Serum IGFBP7 levels associate with insulin resistance and the risk of metabolic syndrome in a Chinese population

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Liu, Yi ^a   Wu, Minliang ^b   Ling, Jie ^a   Cai, Libing ^c   Zhang, Dandan ^b   Gu, Harvest F ^d   Wang, Hao ^b   Zhu, Yimin ^a   Lai, Maode ^b  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c Xiaoshan Hospital   (China)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-RELATED PROTEIN 1; SOMATOMEDIN BINDING PROTEIN;

ADULT; AGED; BLOOD; CASE CONTROL STUDY; CHINA; FEMALE; HEALTH SURVEY; HUMAN; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; RISK;

ADULT; AGED; BIOMARKERS; CASE-CONTROL STUDIES; CHINA; FEMALE; HUMANS; INSULIN RESISTANCE; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; POPULATION SURVEILLANCE; RISK;

EID: 84929448758     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep10227     Document Type: Article

References (40)

1. Alberti, K. G., Zimmet, P., Shaw, J. & Group, I. D. F. E. T. F. C. The metabolic syndrome-a new worldwide definition. Lancet 366, 1059-1062, doi:10.1016/S0140-6736(05)67402-8 (2005).
2. Cameron, A. J., Zimmet, P. Z., Shaw, J. E. & Alberti, K. G. The metabolic syndrome: in need of a global mission statement. Diabet Med. 26, 306-309, doi:10.1111/j.1464-5491.2009.02681.x (2009).
3. Simmons, R. K. et al. The metabolic syndrome: useful concept or clinical tool? Report of a WHO Expert Consultation. Diabetologia 53, 600-605, doi:10.1007/s00125-009-1620-4 (2010).
4. Hunt, K. J., Williams, K., Hazuda, H. P., Stern, M. P. & Haffner, S. M. The metabolic syndrome and the impact of diabetes on coronary heart disease mortality in women and men: the San Antonio Heart Study. Ann. Epidemiol. 17, 870-877, doi:10.1016/j.annepidem.2007.05.012 (2007).
5. Klein, B. E., Klein, R. & Lee, K. E. Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in Beaver Dam. Diabetes Care 25, 1790-1794 (2002).
6. Malik, S. et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 110, 1245-1250, doi:10.1161/01.CIR.0000140677.20606.0E (2004).
7. Alberti, K. G. et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120, 1640-1645, doi:10.1161/CIRCULATIONAHA.109.192644 (2009).
8. Zimmet, P., Alberti, K. G. & Serrano Rios, M. A New International Diabetes Federation (IDF) Worldwide Definition of the Metabolic Syndrome: the Rationale and the Results. Rev. Esp. Cardiol (Engl Ed) 58, 1371-1375, doi:10.1016/S1885-5857(06)60742-1 (2005).
9. Lebovitz, H.E. Insulin resistance: definition and consequences. Exp. Clin Endocrinol Diabetes 109 Suppl 2, S135-48, doi: 10.1055/s-2001-18576 (2001).
10. Sandhu, M. S., Dunger, D. B. & Giovannucci, E. L. Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer. J Natl. Cancer Inst. 94, 972-980 (2002).
11. Dunger, D. B., Ong, K. K. & Sandhu, M. S. Serum insulin-like growth factor-I levels and potential risk of type 2 diabetes. Horm Res 60 Suppl 3, 131-135, doi:74514 (2003).
12. Kaushal, K. et al. The impact of abnormalities in IGF and inflammatory systems on the metabolic syndrome. Diabetes Care 27, 2682-2688 (2004).
13. Sandhu, M. S., Gibson, J. M., Heald, A. H., Dunger, D. B. & Wareham, N. J. Association between insulin-like growth factor-I: insulin-like growth factor-binding protein-1 ratio and metabolic and anthropometric factors in men and women. Cancer Epidemiol Biomarkers Prev. 13, 166-170 (2004).
14. Wu, X. et al. Serum levels of insulin growth factor (IGF-I) and IGF-binding protein predict risk of second primary tumors in patients with head and neck cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 10, 3988-3995, doi:10.1158/1078-0432.CCR-03-0762 (2004).
15. Zhang, P. H. et al. Increased risk of cancer in patients with type 2 diabetes mellitus: a retrospective cohort study in China. BMC Public Health 12, 567, doi:10.1186/1471-2458-12-567 (2012).
16. Ren, X. et al. Type 2 diabetes mellitus associated with increased risk for colorectal cancer: evidence from an international ecological study and population-based risk analysis in China. Public Health 123, 540-544, doi:10.1016/j.puhe.2009.06.019 (2009).
17. Baxter, R. C. et al. Recommendations for nomenclature of the insulin-like growth factor binding protein (IGFBP) superfamily. Growth Horm IGF Res 8, 273-274 (1998).
18. Hwa, V., Oh, Y. & Rosenfeld, R. G. The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocrine reviews 20, 761-787, doi:10.1210/edrv.20.6.0382 (1999).
19. Yamanaka, Y., Wilson, E. M., Rosenfeld, R. G. & Oh, Y. Inhibition of insulin receptor activation by insulin-like growth factor binding proteins. J Biol Chem 272, 30729-30734 (1997).
20. Oh, Y. et al. Synthesis and characterization of insulin-like growth factor-binding protein (IGFBP)-7. Recombinant human mac25 protein specifically binds IGF-I and -II. The Journal of biological chemistry 271, 30322-30325 (1996).
21. Lopez-Bermejo, A. et al. Insulin resistance is associated with increased serum concentration of IGF-binding protein-related protein 1 (IGFBP-rP1/MAC25). Diabetes 55, 2333-2339, doi:10.2337/db05-1627 (2006).
22. Collet, C. & Candy, J. How many insulin-like growth factor binding proteins? Molecular and cellular endocrinology 139, 1-6 (1998).
23. Ma, Y. et al. Tumor suppressor gene insulin-like growth factor binding protein-related protein 1 (IGFBP-rP1) induces senescence-like growth arrest in colorectal cancer cells. Exp. Mol. Pathol. 85, 141-145, doi:10.1016/j.yexmp.2008.04.005 (2008).
24. Ruan, W. et al. IGFBP7 plays a potential tumor suppressor role in colorectal carcinogenesis. Cancer Biol. Ther. 6, 354-359 (2007).
25. Ruan, W. J. et al. IGFBP7 plays a potential tumor suppressor role against colorectal carcinogenesis with its expression associated with DNA hypomethylation of exon 1. J. Zhejiang Univ. Sci. B 7, 929-932, doi:10.1631/jzus.2006.B0929 (2006).
26. Vizioli, M. G. et al. IGFBP7: an oncosuppressor gene in thyroid carcinogenesis. Oncogene 29, 3835-3844, doi:10.1038/onc.2010.136 (2010).
27. Jiang, W., Xiang, C., Cazacu, S., Brodie, C. & Mikkelsen, T. Insulin-like growth factor binding protein 7 mediates glioma cell growth and migration. Neoplasia 10, 1335-1342 (2008).
28. Kutsukake, M. et al. Circulating IGF-binding protein 7 (IGFBP7) levels are elevated in patients with endometriosis or undergoing diabetic hemodialysis. Reprod Biol. Endocrinol 6, 54, doi:10.1186/1477-7827-6-54 (2008).
29. Gu, H. F. et al. Evaluation of IGFBP-7 DNA methylation changes and serum protein variation in Swedish subjects with and without type 2 diabetes. Clinical epigenetics 5, doi:Artn 20 Doi 10.1186/1868-7083-5-20 (2013).
30. Li, F. et al. Methylation of serum insulin-like growth factor-binding protein 7 promoter in hepatitis B virus-associated hepatocellular carcinoma. Genes, chromosomes & cancer 53, 90-97, doi:10.1002/gcc.22120 (2014).
31. Chen, D. et al. Insulin-like growth factor-binding protein-7 (IGFBP7): a promising gene therapeutic for hepatocellular carcinoma (HCC). Molecular therapy: the journal of the American Society of Gene Therapy 21, 758-766, doi:10.1038/mt.2012.282 (2013).
32. An, W. et al. Low expression of IGFBP7 is associated with poor outcome of pancreatic ductal adenocarcinoma. Annals of surgical oncology 19, 3971-3978, doi:10.1245/s10434-012-2407-2 (2012).
33. Huang, Y. J. et al. The functional IGFBP7 promoter -418G> A polymorphism and risk of head and neck cancer. Mutat Res. 702, 32-39, doi:10.1016/j.mrgentox.2010.06.012 (2010).
34. Shao, L., Huang, Q., Luo, M. & Lai, M. Detection of the differentially expressed gene IGF-binding protein-related protein-1 and analysis of its relationship to fasting glucose in Chinese colorectal cancer patients. Endocrine-related cancer 11, 141-148 (2004).
35. Zhan, Y. et al. Serum insulin-like, growth factor binding protein-related protein 1 (IGFBP-rP1) and endometrial cancer risk in Chinese women. International journal of cancer. Journal international du cancer 132, 411-416, doi:10.1002/ijc.27622 (2013).
36. Bonnet, C. et al. Characterization of mosaic supernumerary ring chromosomes by array-CGH: segmental aneusomy for proximal 4q in a child with tall stature and obesity. American journal of medical genetics. Part A 140, 233-237, doi:10.1002/ajmg.a.31075 (2006).
37. Crossey, P. A., Jones, J. S. & Miell, J. P. Dysregulation of the insulin/IGF binding protein-1 axis in transgenic mice is associated with hyperinsulinemia and glucose intolerance. Diabetes 49, 457-465 (2000).
38. Grundy, S. M. Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. The American journal of cardiology 83, 25f-29f (1999).
39. Guo, S. Insulin signaling, resistance, and the metabolic syndrome: insights from mouse models into disease mechanisms. The Journal of endocrinology 220, T1-t23, doi:10.1530/joe-13-0327 (2014).
40. Lopez-Bermejo, A. et al. Insulin-like growth factor binding protein-related protein 1 (IGFBP-rP1/MAC25) is linked to endothelial-dependent vasodilation in high-ferritin type 2 diabetes. Diabetes Care. 30, 1615-1617, doi:10.2337/dc06-1905 (2007).